44 results about "Tongue squamous cell carcinoma" patented technology

The invention discloses application of a reagent capable of promoting circular RNA (Ribonucleic Acid) circRNF13 expression to preparation of a medicine for treating tongue squamous cell carcinoma. A research proves that circRNF13 is overexpressed in tongue squamous cell carcinoma cells and the proliferation of the tongue squamous cell carcinoma cells can be inhibited. Therefore, a circRNF13 overexpression preparation is used for treating the tongue squamous cell carcinoma and has profound clinical significance and an important popularization and application prospect.

The invention discloses a tongue squamous carcinoma diagnosis and treatment target-AMTN gene. Whether asubject suffers from the tongue squamous carcinoma or not can be judged or whether the risk that asubject suffers from the tongue squamous carcinomaexists or not can be diagnosed by detecting the AMTN gene in the bone marrow tissue of the subject and the content of it expression product. In addition, it is proved through research on proliferationindexes of tongue squamous carcinoma cells cultured in vitro that the AMTN gene is used as a drug target for treating the tongue squamous carcinoma.

The invention discloses a preparation method and application of bacterial wall-modified liposome-loaded doxorubicin, which comprises dissolving soybean lecithin, cholesterol and doxorubicin in an organic solvent and rotary evaporation to obtain a dry lipid film ; The lipid film is hydrated, and the bacterial wall is added while hydrating to obtain DOX‑BW‑LP; the bacterial wall is the bacterial wall of Staphylococcus aureus. In the present invention, bacterial wall fusion liposomes are prepared into immunoliposomes, which act on human tongue squamous cell carcinoma cells, and it is found that the bacterial wall of Staphylococcus aureus prepared by the present invention has an immunoregulatory effect on macrophages, and induces macrophages to M1 polarization can enhance the recognition and phagocytosis of macrophages on tumor cells, and realize the functions of killing tumors and inhibiting tumor growth. The multiple roles of tumors provide new ideas for immunotherapy of oral cancer.

The invention discloses a PNLIPRP3 gene which can be adopted as a molecular marker for tongue squamous carcinoma diagnosis and treatment. Experiments show that compared with normal tissue, the PNLIPRP3 gene is low in expression quantity in tongue squamous carcinoma tissue. The invention further discloses application of the PNLIPRP3 gene for preparing a drug for tongue squamous carcinoma treatment. The invention provides a novel tongue squamous carcinoma clinic treatment method, and further provides a novel drug target for tongue squamous carcinoma treatment.

The invention discloses application of a reagent for detecting cyclic RNA circRNF13 in preparing a prognosis preparation for tongue squamous cell carcinoma patients, in particular to a preparation forprognosis of the tongue squamous cell carcinoma patients by using a real-time fluorescence quantitative analysis method. The survival analysis of the expression of the circRNF13 in tongue squamous cell carcinoma tissues and the survival time and status of the patients shows that the average survival time of patients who do not express the circRNF13 in the tongue squamous cell carcinoma tissues issignificantly shorter than that of patients with higher expression of the circRNF13. The circRNF13 is a molecular marker associated with the prognosis of the tongue squamous cell carcinoma; the circRNF13 is low in expression or is not expressed, which causes poor prognosis of the patients.

The invention discloses application of a reagent capable of promoting circular RNA (Ribonucleic Acid) circRNF13 expression to preparation of a medicine for treating tongue squamous cell carcinoma. A research proves that circRNF13 is overexpressed in tongue squamous cell carcinoma cells and the proliferation of the tongue squamous cell carcinoma cells can be inhibited. Therefore, a circRNF13 overexpression preparation is used for treating the tongue squamous cell carcinoma and has profound clinical significance and an important popularization and application prospect.

The invention discloses a Chinese medicinal compound with a tongue squamous cell carcinoma resisting effect and a preparation method thereof. The Chinese medicinal compound is prepared from the following raw materials in parts by weight: 10-20 parts of waxgourd seed, 12-24 parts of rhizoma pinellinae praeparata, 10-20 parts of arisaema cum bile, 12-24 parts of indian iphigenia bulb, 10-20 parts of ternate buttercup root, 10-20 parts of wild buckwheat rhizome, 10-20 parts of heartleaf houttuynia herb, 15-30 parts of hairyvein agrimonia herb and bud, 12-24 parts of sappan wood, 15-30 parts of safflower, 10-20 parts of straight ladybell root, 10-20 parts of fragrant solomonseal rhizome and 10-20 parts of dwarf lilyturf root. The Chinese medicinal compound with the tongue squamous cell carcinoma resisting effect provided by the invention is prepared by selecting raw materials according to the traditional Chinese medicine theory and the pathogenesis of tongue squamous cell carcinoma, and components are blended scientifically and reasonably; and as proved by a pharmacodynamics experiment result, the Chinese medicinal compound can contribute to remarkably lowering the content of PGE2, has a very good tongue squamous cell carcinoma resisting effect, is free from untoward effects after long-term use, and can be developed into a new generation of tongue squamous cell carcinoma resisting medicament.

The invention discloses applications of C6orf58 gene as an early stage diagnosis molecular marker of tongue squamous carcinoma. It is confirmed by experiments that: compared with normal mucous tissue, C6orf58 gene expression level of tongue squamous carcinoma tissue is increased obviously; and it is confirmed by RNA interface experiment that C6orf58 is capable of influencing proliferation of tongue squamous carcinoma cells. Drugs used for inhibiting C6orf58 gene expression can be developed based on the invention so as to realize clinical prevention and treatment of tongue squamous carcinoma.

The invention provides a novel target gene for diagnosing and treating tongue squamous carcinoma and application thereof and particularly relates to application of a KLK14 gene and an expression product thereof to diagnosis and treatment of tongue squamous carcinoma. To research the occurrence and development mechanisms of tongue squamous carcinoma, search for an effective molecular target gene for diagnosing and treating tongue squamous carcinoma, promote early diagnosis, prevention and treatment of the disease and lower the death rate of tongue cancer, firstly, RNA-seq sequencing is utilized to detect differential expression genes of tongue squamous carcinoma, cancer branch and normal oral mucosa; secondly, a Real-time PCR technology is utilized to verify the sequencing result; then, an interference technology is utilized, and expression of the candidate gene KLK14 in tongue squamous carcinoma cells SCC15 is silenced. By means of the novel target gene for diagnosing and treating tongue squamous carcinoma and application thereof, an experimental foundation is laid for clinical application of the KLK14 gene to tongue squamous carcinoma, and a new target gene and theoretical basis are provided for early diagnosis and treatment of tongue squamous carcinoma.

The invention discloses a shRNA, a lentiviral vector and its construction method and application for inhibiting the expression of human EDARADD gene. Firstly, the forward strand and the reverse strand of the DNA oligo aiming at the RNA interference target sequence are synthesized; the forward strand and the reverse strand are annealed to form a band Double-stranded DNA at the cohesive end; linearize the lentiviral vector by enzyme digestion, connect the linearized vector to the double-stranded DNA; transform the ligated product into E. coli competent cells, and perform PCR identification on the positive clones obtained; plasmid extraction, For the next step of virus packaging. The present invention uses the EDARADD gene as a template to design the RNA interference target sequence, designs the shRNA interference sequence according to the selected target sequence, packages and constructs the RNA interference lentiviral vector, and knocks down the EDARADD gene, which will significantly affect the CAL of tongue squamous cell carcinoma cells Proliferation of ‑27 cells, affecting cell clone formation ability, and promoting cell apoptosis.

The invention belongs to the field of biological medicines, and discloses application of a GAGE2D gene used as a diagnosis and treatment marker for tongue squamous carcinoma. An experiment provided by the invention proves that the expression of the GAGE2D gene in normal tissues is significantly different from that in tongue squamous carcinoma tissues. According to the correlation between the GAGE2D gene and the tongue squamous carcinoma, the GAGE2D gene can be used as a novel molecular marker for clinically diagnosing the tongue squamous carcinoma, and can also be used as a novel target of a medicine for treating the tongue squamous carcinoma at the same time.

The invention belongs to the field of the biopharmaceutical research, and particularly relates to application of a MTHFD1L (methylenetetrahydrofolate dehydrogenase (NADP+dependent)1like) inhibitor. Bywide and deep research, the invention shows that MTHFD1L can be used as a tongue squamous cell carcinoma treatment target for the first time. The MTHFD1L inhibitor can inhibit cell multiplication oftongue squamous cell carcinoma, promote cell apoptosis of tongue squamous cell carcinoma, inhibit cell cloning, inhibit tumorigenesis of tongue squamous cell carcinoma, treat tongue squamous cell carcinoma and develops a new direction for treatment of tongue squamous cell carcinoma.

The invention discloses a PNLIPRP3 gene which can be adopted as a molecular marker for tongue squamous carcinoma diagnosis and treatment. Experiments show that compared with normal tissue, the PNLIPRP3 gene is low in expression quantity in tongue squamous carcinoma tissue. The invention further discloses application of the PNLIPRP3 gene for preparing a drug for tongue squamous carcinoma treatment. The invention provides a novel tongue squamous carcinoma clinic treatment method, and further provides a novel drug target for tongue squamous carcinoma treatment.

The invention discloses a genetic marker. The genetic marker is ACTA1. ACTA1 can be used for determining whether a subject has a risk of suffering from the tongue squamous cell carcinoma or not or determining whether the subject suffers from the tongue squamous cell carcinom or not. In addition, ACTA1 also can be used for preparing drugs for treatment of the tongue squamous cell carcinoma. The invention provides a new diagnostic method for clinical diagnosis of the tongue squamous cell carcinoma at the molecular level and further provides a new drug target for gene therapy of the tongue squamous cell carcinoma.